Is the price fair?
What MIRM's price assumes
Mirum Pharmaceuticals, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 9.54× revenue.
9.54
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 22.4
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 22.4
- EV / EBIToperating margin −135%: the multiple describes the denominator
- not meaningful
- Market capitalisation
- $7.15B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.